Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/59865
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChumnan Kietpeerakoolen_US
dc.contributor.authorJatupol Srisomboonen_US
dc.date.accessioned2018-09-10T03:22:44Z-
dc.date.available2018-09-10T03:22:44Z-
dc.date.issued2009-02-01en_US
dc.identifier.issn13419625en_US
dc.identifier.other2-s2.0-60649093969en_US
dc.identifier.other10.1007/s10147-008-0795-xen_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=60649093969&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/59865-
dc.description.abstractCervical intraepithelial neoplasia (CIN) II, III is a preinvasive stage of squamous cell carcinoma of the uterine cervix. The standard treatment for CIN II, III consists of ablation and excision. However, nonsurgical treatment may be necessary for some women to preserve future reproductive potential. This review was conducted to summarize available published data on the efficacy and safety of medical treatment for CIN II, III. Based on existing studies, cyclooxygenase (COX)-2 inhibitors; indole-3-carbinol; and novel immunotherapy agents, including ZYC101a, MVA E2, and HspE7, have been observed as possessing therapeutic activity without any major treatment-related complications. These promising results provide important data for the future direction of clinical research. © 2009 Japan Society of Clinical Oncology.en_US
dc.subjectMedicineen_US
dc.titleMedical treatment of cervical intraepithelial neoplasia II, III: An update reviewen_US
dc.typeJournalen_US
article.title.sourcetitleInternational Journal of Clinical Oncologyen_US
article.volume14en_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.